Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Department of War (DoW) is issuing a Request for Quotation (RFQ) for pharmaceutical agents to be included in the Military Health System's Uniform Formulary (UF). This RFQ outlines the process for manufacturers to submit offers for UF Blanket Purchase Agreements (BPA) and UF Additional Discount Program (ADP) agreements, which aim to reduce DoW costs for pharmaceuticals. The DoW Pharmacy and Therapeutics (P&T) Committee will evaluate submissions based on clinical and cost-effectiveness to classify agents as generic, formulary, or non-formulary. The document details submission instructions, evaluation criteria, and relevant definitions, along with appendices for manufacturer checklists, BPA, ADP, and NDC Price Lists. Key dates for teleconferences and quote submissions are also provided.

The document outlines a federal government Request for Quote (RFQ) process for ADHD agents, specifically stimulants, under the DoW Uniform Formulary and Additional Discount Programs. Quotes for these drugs are due by April 27, 2026, for consideration at the P&T Committee Meeting on May 6-7, 2026. The file details various scenarios for both Uniform Formulary and Non-Formulary drugs within the Blanket Purchase Agreement Appendix, and for Tier 2 and Tier 3 drugs under the Additional Discount Program Appendix. Manufacturers are instructed to submit a Quote Review Checklist and fully executed signature pages. The document also provides notes on Prior Authorization (PA), potential for special reimbursement methods, and the possibility of designating non-step preferred agents. It clarifies that the price per unit will be consistent across all package sizes within a dispensing venue for the BPA, and explains the calculation of the Total Calculated Refund Per FCP and the use of Wholesale Acquisition Cost (WAC) for products without a Federal Ceiling Price.

This government file details the DoW Uniform Formulary Class for Skeletal Muscle Relaxants and Combinations, outlining the process for newly approved drugs. It includes Blanket Purchase Agreement Appendices and Additional Discount Program Appendices for ten different entries within this drug class. Key dates are provided: the P&T Committee Meeting scheduled for May 6-7, 2026, and the deadline for quotes on April 27, 2026. The document specifies that agents will be reviewed according to 32 CFR 199.21(g)(5) and may be subject to Prior Authorization. The P&T Committee may recommend preferential status for non-generic agents (Tier 1) or complete exclusion from the TRICARE pharmacy benefit program. Manufacturers are reminded to submit the Quote Review Checklist and executed signature pages along with their quote information. The file also describes how prices per unit will be consistent across package sizes and details the calculation of retail refunds based on non-FAMP and Federal Ceiling Price (FCP), as well as WAC pricing for products without an FCP.

The Department of Defense (DoD) Uniform Formulary Class for "TARGETED IMMUNOMODULATORY BIOLOGICS" outlines pricing and reimbursement guidelines for pharmaceutical agents, with quotes due by April 27, 2026, for a P&T Committee Meeting on May 6-7, 2026. The document details two appendices: a Blanket Purchase Agreement for newly approved drugs and an Additional Discount Program. Both emphasize prior authorization, step therapy, and potential preferential status for high-value products or exclusion for low-value ones. Biosimilars will not have grandfathering for step therapy. Manufacturers must submit a Quote Review Checklist and signature pages. The document specifies pricing per unit for all package sizes and details retail refund calculations based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) for eligible drugs.

The document outlines the DoW Uniform Formulary Class for "ENDOCRINE AGENTS MISCELLANEOUS" and the associated P&T Committee Meeting scheduled for May 6-7, 2026, with quotes due by April 27, 2026. It details requirements for Blanket Purchase Agreements and an Additional Discount Program for newly approved drugs. Manufacturers are instructed to submit Quote Review Checklists and executed signature pages. The file specifies that agents will be reviewed according to 32 CFR 199.21(g)(5) and may be subject to Prior Authorization. The P&T Committee may recommend preferential status or exclusion from the TRICARE pharmacy benefit program. Pricing for military treatment facilities and mail-order pharmacies, as well as TRICARE retail refunds, are discussed, with scenarios for uniform and non-formulary categories, and Tier 2 and Tier 3 classifications. The document also provides calculations for retail refunds based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) for applicable products.

This government file details the Department of War (DoW) Uniform Formulary Class for Metabolic Dysfunction Agents, specifically Weight Loss Agents. It outlines the process for newly approved drugs, with quotes due by April 27, 2026, for consideration at the P&T Committee Meeting on May 6-7, 2026. The document includes sections for Blanket Purchase Agreement Appendix and Additional Discount Program Appendix, both specifying NDC numbers for Uniform Formulary/Non-Formulary and Tier 2/Tier 3 drugs, respectively. Manufacturers are instructed to submit Quote Review Checklists and executed signature pages. Key notes highlight that Prior Authorization may apply, agents could be candidates for special reimbursement or complete exclusion from TRICARE, and a 'no grandfathering' step therapy addendum is in effect. The file also clarifies pricing mechanisms, including price per unit and retail refund calculations based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC).

This government file outlines the DOW Uniform Formulary Class for TARGETED IMMUNOMODULATORY BIOLOGICS, specifically the INTERLEUKIN 23 subclass, with P&T Committee meetings scheduled for May 6-7, 2026, and quotes due by April 27, 2026. The document includes several "Blanket Purchase Agreement Appendix – Newly Approved Drug" sections and "Additional Discount Program Appendix – Newly Approved Drug" sections, each detailing NDC numbers and formulary scenarios. Key notes indicate that Prior Authorization (PA) may apply, agents may be considered for special reimbursement or preferential status (Tier 1), or even exclusion from the TRICARE pharmacy benefit. Step therapy addendums clarify grandfathering rules for new patients for traditional agents, while biosimilars will not have grandfathering. The P&T Committee will consider removing step preferences for the TIBS class for select indications, and agents without submitted or selected RFQs may be designated non-step preferred. Manufacturers are reminded to submit fully executed signature pages with quote information. The document also details the calculation of retail refunds based on Non-FAMP and Federal Ceiling Price (FCP), and the use of Wholesale Acquisition Cost (WAC) for products without FCP.

This document outlines the Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) appendices for newly approved "METABOLIC AGENTS - MISCELLANEOUS" drugs, slated for review at the DoW P&T Committee Meeting on May 6-7, 2026. Quotes for these agents are due by April 27, 2026. The file details formulary scenarios for uniform and non-formulary drugs under the BPA, with specific NDC numbers listed for each. It also outlines TRICARE Retail Refund scenarios for Tier 2 and Tier 3 drugs under the ADP, including calculations based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) where applicable. Manufacturers are reminded to submit the Quote Review Checklist and executed signature pages, with a note that the P&T Committee may recommend special reimbursement methods, preferential status, or even exclusion from the TRICARE pharmacy benefit program. Prior Authorization (PA) may apply, and agents without submitted or selected RFQs might be designated non-step preferred (after-step).

The document outlines the DoW Uniform Formulary Class ANTILIPIDEMICS-1, subclass PCSK-9, with quotes due by April 27, 2026, for a P&T Committee Meeting on May 6-7, 2026. It details requirements for Blanket Purchase Agreements and an Additional Discount Program for newly approved drugs. Key formulary considerations include Prior Authorization (PA) and step therapy, with generic agents as a first step. Drugs with an ingredient cost under $250 per 30-day supply may be considered for Uniform Formulary (UF) or Tier 2, potentially reducing step therapy requirements and removing annual PA renewals. Drugs exceeding $250 for a 30-day supply may be designated Non-Formulary (NF) or Tier 3, or even completely excluded, with additional PA requirements. Manufacturers must submit a Quote Review Checklist and executed signature pages. The document also provides specifics on TRICARE Retail Refunds, Federal Ceiling Price (FCP), Non-FAMP, and Wholesale Acquisition Cost (WAC) for calculating refunds and pricing.

This government file outlines the "UF BPA NDC Price List" and "UF ADP Appendix" for newly approved drugs in the "METABOLIC AGENTS - MISCELLANEOUS" class, specifically "REPLACEMENT ENZYMES." Quotes for these drugs are due by April 27, 2026, with the P&T Committee Meeting scheduled for May 6-7, 2026. The document details two scenarios for both Uniform Formulary and Non-Formulary drugs under the Blanket Purchase Agreement (BPA) Appendix, and Tier 2 and Tier 3 drugs under the Additional Discount Program (ADP) Appendix. Manufacturers are instructed to submit a "Quote Review Checklist" and executed signature pages. The file also notes that prior authorization may apply, and the P&T Committee may recommend preferential status for non-generic agents or even complete exclusion from the TRICARE pharmacy benefit program. It emphasizes consistent pricing per unit across all package sizes and details how retail refunds are calculated, including Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) considerations.

The document outlines the DoW Uniform Formulary Class for "GROWTH STIMULATING AGENTS" for the May 6-7, 2026, P&T Committee Meeting, with quotes due by April 27, 2026. It details Blanket Purchase Agreement (BPA) Appendix and Additional Discount Program (ADP) Appendix information for newly approved drugs. Key considerations include Prior Authorization (PA), potential for special reimbursement methods to encourage high-value products, and the possibility of designating non-generic agents as Tier 1 or excluding certain drugs from TRICARE. Step therapy without grandfathering is mandated, requiring new patients to trial step-preferred agents first. Formulary considerations are triggered if the net ingredient cost exceeds $1500 per four weeks of therapy. Manufacturers must submit a Quote Review Checklist and executed signature pages along with quote information. The document also specifies refund calculation methodologies for TRICARE Retail Refund based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) for products without FCP.

This document outlines instructions for completing a Price Appendix FAQ spreadsheet, focusing on three pricing methodologies: BPA, ADP (non-FAMP Discount), and ADP (WAC Discount). For each section, it emphasizes reading the Formulary Notes, filling in yellow cells, and understanding auto-calculated fields. Key instructions include how to indicate not submitting a quote (cells highlighting red), managing NDC submissions (up to 10 tables provided, with options to request more), and contacting Points of Contact (POCs) for questions. The document details specific calculations for Price per Unit in BPA and Total Calculated Refund in ADP (non-FAMP Discount), and clarifies that WAC is for products without FCP or covered drugs. This guide ensures accurate completion of pricing data for government RFPs.

The Final Rule, published on July 27, 2015, clarifies the process for formulary placement of newly approved innovator drugs within the DoD's TRICARE Pharmacy Benefits Program. It grants the Pharmacy and Therapeutics (P&T) Committee up to 120 days to recommend tier placement for FDA-approved innovator drugs, including new molecular entities and dosage forms. Drugs approved on or after August 26, 2015, will have a pending status and be treated as non-formulary. The DHA Director has final approval authority for P&T Committee recommendations. The Committee will evaluate cost-effectiveness using available pricing and solicit price concessions from manufacturers. Innovator drugs are generally designated as Tier 3, requiring medical necessity for availability at Military Treatment Facilities (MTFs) or a lower copay through TRICARE Mail Order Pharmacy (TMOP) and retail pharmacies. The DoD will not accept clinical presentations from manufacturers due to the volume of new drugs.